[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620387":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":10,"responsibleParty":22,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":30,"eligibilityCriteria":31,"healthyVolunteers":26,"sex":32,"minAge":33,"maxAge":10,"enrollmentInfo":34,"targetDuration":10,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":42,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Gruppo Italiano Malattie EMatologiche dell'Adulto","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients treated with ponatinib in first line",null,"Patients treated with ponatinib as first line, alone or in combination with other antileukaemic agents, under Law 648\u002F96.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Paola Fazi","CONTACT","0039 0670390528","p.fazi@gimema.it",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Enrico Crea","0039 0670390514","e.crea@gimema.it",{"type":23,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100620387","evaluation-of-the-efficacy-of-ponatinib-in-ph-all-in-the-real-world-100620387",false,"NCT07356960","Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world","Retrospective, Observational, Study on the Evaluation of the Real-world Outcome of Philadelphia-positive Acute Lymphoblastic Leukaemia Patients Treated With Ponatinib as First-line Treatment Under the Italian Law 648\u002F96 (PONA4ALL Ph+)","PONA4ALL Ph+","Inclusion Criteria:\n\n1. Patient is \\> 18 years old;\n2. Patient was treated in first-line with ponatinib monotherapy or in association with chemotherapy or immunotherapy;\n3. Patient received ponatinib under the regulations of Law 648\u002F96;\n4. \\- Patient is alive and have at least 18 months of retrospective observation available from the start of ponatinib treatment, OR\n\n   \\- has died\u002Flost to follow-up at any time after treatment initiation, regardless of the length of available follow-up;\n5. Signed informed consent, if applicable.\n\nExclusion Criteria:\n\n* None","ALL","18 Years",{"count":35,"type":36},103,"ESTIMATED","OBSERVATIONAL","The goal of this retrospective observational study is to learn about the efficacy of ponatinib in Philadelphia-positive ALL (Ph+ ALL) patients in a real-world setting. The main goal of the study is to assess the rate of complete molecular response (CMR) induced by ponatinib in patients treated under the regulations of Law 648\u002F96, outside clinical trials.\n\nPatients who were treated with ponatinib as part of their regular medical care and completed the follow-up period will be included in the study.",[40,41],"Acute Lymphobkastic Leukemia","Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",[43,44,45,46,47],"ponatinib","real-world","philadelphia-positive acute lymphoblastic leukemia","Ph+ ALL","adult","NOT_YET_RECRUITING","2026-01-12",{"date":51,"type":52},"2026-01-21","ACTUAL",{"date":54,"type":36},"2026-04-02",{"date":56,"type":36},"2029-06-30",{"name":5,"class":6}]